Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis. Issue 6 (November 2021)

• Record Type: Journal Article
• Authors: Nichelli, Lucia; Casagranda, Stefano
• Is Part Of: Current opinion in oncology. Volume 33:Issue 6(2021)
• Publication Date: 2021-11
• Subjects: advanced MRI -- amide proton transfer weighted imaging -- brain tumor -- pseudoprogression -- radionecrosis; Oncology -- Periodicals; 616.994
• DOI: 10.1097/CCO.0000000000000793
• Languages: English
• ISSNs: 1040-8746

Abstract

Abstract : Purpose of review: This review aims to cover current MRI techniques for assessing treatment response in brain tumors, with a focus on radio-induced lesions. Recent findings: Pseudoprogression and radionecrosis are common radiological entities after brain tumor irradiation and are difficult to distinguish from real progression, with major consequences on daily patient care. To date, shortcomings of conventional MRI have been largely recognized but morphological sequences are still used in official response assessment criteria. Several complementary advanced techniques have been proposed but none of them have been validated, hampering their clinical use. Among advanced MRI, brain perfusion measures increase diagnostic accuracy, especially when added with spectroscopy and susceptibility-weighted imaging. However, lack of reproducibility, because of several hard-to-control variables, is still a major limitation for their standardization in routine protocols. Amide Proton Transfer is an emerging molecular imaging technique that promises to offer new metrics by indirectly quantifying intracellular mobile proteins and peptide concentration. Preliminary studies suggest that this noncontrast sequence may add key biomarkers in tumor evaluation, especially in posttherapeutic settings. Summary: Benefits and pitfalls of conventional and advanced imaging on posttreatment assessment are discussed and the potential added value of APT in this clinicoradiological evolving scenario is introduced.